Keyphrases
Transforming Growth Factor-β
80%
Coronary Vessel Development
72%
Epicardial Cells
66%
Epicardium
58%
Malignancy
52%
Coronary Vessels
46%
Chronic Lymphocytic Leukemia
44%
Eruptive Keratoacanthoma
33%
Demodicosis
33%
Entity Management
33%
Eosinophilic Dermatosis
33%
Overgrowth Syndrome
33%
Tumor Classification
33%
Mesenchymal Neoplasm
33%
Melanoma
33%
DNMT3A
33%
Genetic Characterization
33%
Excision Margins
33%
Follicular mucinosis
33%
Vulvovaginitis
33%
Demodex
33%
Acneiform
33%
Eosinophilic Folliculitis
33%
Eosinophilic Dermatosis of Hematologic Malignancy
33%
Risk of Death
33%
Eosinophils
33%
Progress Management
33%
Anticancer Therapy
33%
Disease Entity
33%
Atypia
33%
Eyelid
33%
Regular Type
33%
Merkel Cell Carcinoma
33%
KDM6A
33%
Vulvar
33%
B-cell Lymphoma
33%
Squamous Cell Skin Cancer
33%
5-fluorouracil (5-FU)
33%
Smooth muscle Cell Differentiation
33%
Diagnostic Marker
33%
Cutaneous Squamous Cell Carcinoma (cSCC)
33%
Trp53
33%
Wide Local Excision
33%
Dermatomyositis
33%
Novel Diagnostics
33%
Relapse Risk
33%
BCL6
33%
Expert Clinician
33%
Information Sharing
33%
Feature Information
33%
Medicine and Dentistry
Cancer Growth Factor
100%
Coronary Vessel
72%
Dermatosis
66%
Eosinophilic
66%
Epicardium
63%
Cancer
56%
Smooth Muscle
53%
Disease
50%
Hematologic Malignancy
44%
Folliculitis
44%
Cell Differentiation
38%
Demodicosis
33%
Wide Local Excision
33%
Merkel Cell Carcinoma
33%
Keratoacanthoma
33%
Repressor Gene
33%
Tumor Classification
33%
Eyelid
33%
DNA Methyltransferase 3A
33%
Vulvovaginitis
33%
Surgical Margin
33%
Diffuse Large B-Cell Lymphoma
33%
Diagnostic Marker
33%
Transcription Factors
33%
Alopecia Mucinosa
33%
B-Cell Lymphoma
33%
Dermatomyositis
33%
Fluorouracil
33%
Clinician
33%
Histopathology
33%
Cancer Treatment
33%
Cancer Cell
33%
Growth Factor Receptor
33%
Smooth Muscle Cell
33%
Connective Tissue Cancer
33%
Melanoma
33%
Biopsy Technique
32%
Muscle Development
30%
Eosinophil
27%
Rho Kinase
25%
B-Cell Chronic Lymphocytic Leukemia
25%
Hazard Ratio
23%
Fordyce Spots
22%
Labia Minora
22%
Lymphocytic Lymphoma
19%
Recurrence Free Survival
16%
Papular Rash
16%
Receptor
16%
Vulva
15%
Vascularity
15%
